Results 81 to 90 of about 16,133 (222)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity

Scientific Reports, 2022
Efavirenz is metabolized by CYP2B6, an inducible enzyme whose expression is regulated by the constitutive androstane receptor and pregnane X receptor nuclear receptors. CAR and PXR are encoded by genetically polymorphic NR1I2 and NR1I3, respectively.
Zelalem Petros, Abiy Habtewold, Eyasu Makonnen, Eleni Aklillu   +3 more
doaj   +1 more source

Influence of Tramadol on the Intravenous Pharmacokinetics of Dipyrone Active Metabolites in Dogs

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT This study aimed to compare the pharmacokinetic profile of the active dipyrone metabolites 4‐methylaminoantipyrine (MAA) and 4‐aminoantipyrine (AA) administered alone and in combination with tramadol in dogs. Nine mixed‐breed dogs, weighing 15.33 ± 2.25 kg, participated in a two‐treatment crossover design: G1 received intravenous dipyrone (25 ...
Andressa Nunes Mouta, Kathryn Nóbrega Arcoverde, Robson dos Anjos Honorato, Naftáli Silva Fernandes, Caio Vinicius Almeida de Oliveira, Glícia Cavalcante Mesquita, Yanna Deysi Bandeira Passos, Gabriel Araújo‐Silva, Valéria Veras de Paula   +8 more
wiley   +1 more source

CYP2B6*6 is associated with increased breast cancer risk [PDF]

International Journal of Cancer, 2013
The cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of testosterone. Functional changes in this enzyme may influence endogenous hormone exposure, which has been associated with risk of breast cancer. To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and ...
Justenhoven, Christina, Pentimalli, Daniela, Rabstein, Sylvia, Harth, Volker, Lotz, Anne, Pesch, Beate, Brüning, Thomas, Dörk, Thilo, Schürmann, Peter, Bogdanova, Natalia, Park-Simon, Tjoung-Won, Couch, Fergus J., Olson, Janet E., Fasching, Peter A., Beckmann, Matthias W., Häberle, Lothar, Ekici, Arif, Hall, Per, Czene, Kamilla, Liu, Janjun, Li, Jingmei, Baisch, Christian, Hamann, Ute, Ko, Yon-Dschun, Brauch, Hiltrud   +24 more
openaire   +2 more sources

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma

Scientific Reports, 2023
Cyclophosphamide, an oxazaphosphorine prodrug is frequently used in treatment of neuroblastoma, which is one of the most prevalent solid organ malignancies in infants and young children.
Katalin Mangó, Ferenc Fekete, Ádám Ferenc Kiss, Réka Erdős, János Tibor Fekete, Tamás Bűdi, Edit Bruckner, Miklós Garami, Tamás Micsik, Katalin Monostory   +9 more
doaj   +1 more source

Causal Effect Estimation With TMLE: Handling Missing Data and Near Violations of Positivity

Biometrical Journal, Volume 68, Issue 3, June 2026.
ABSTRACT We evaluate the performance of targeted maximum likelihood estimation (TMLE) for estimating the average treatment effect in missing data scenarios under varying levels of positivity violations. We employ model‐ and design‐based simulations, with the latter using undersmoothed highly adaptive lasso on the “WASH Benefits Bangladesh” data set to ...
Christoph Wiederkehr, Christian Heumann, Michael Schomaker   +2 more
wiley   +1 more source

The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer. [PDF]

, 2017
Activating transcription factor 5 (ATF5) is a cellular prosurvival transcription factor within the basic leucine zipper (bZip) family that is involved in cellular differentiation and promotes cellular adaptation to stress.
Angelastro, James M, Sears, Thomas K
core   +2 more sources

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana

Pharmacogenomics and Personalized Medicine, 2021
Monkgomotsi J Maseng,1,2 Leabaneng Tawe,1– 3 Prisca K Thami,2,4 Kaelo K Seatla,1,2 Sikhulile Moyo,2,5 Axel Martinelli,6 Ishmael Kasvosve,1 Vladimir Novitsky,2,5 Max Essex,2,5 Gianluca Russo,7 Simani Gaseitsiwe,2,5 Giacomo M Paganotti3,8,9 1School ...
Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM   +11 more
doaj  

Pluripotent stem cell-derived hepatocyte-like cells [PDF]

, 2014
Liver disease is an important clinical problem, impacting over 30 million Americans and over 600 million people worldwide. It is the 12th leading cause of death in the United States and the 16th worldwide.
Bhatia, Sangeeta N, Fleming, Heather, Khetani, Salman R., Schwartz, Robert E.   +3 more
core   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source